Die FDA bietet keinen selbst aktualisierenden News-Dienst an, Informationen über aktuelle FDA-Zulassungen können auf der FDA-Homepage eingesehen werden.

Der kommerzielle Anbieter drugs.com publiziert einen Nachrichtendienst mit Informationen zu allen Neuzulassungen der FDA.

• U.S. FDA Grants Full Approval of Kite’s Tecartus for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
  03.04.2026
  SANTA MONICA, Calif. – April 2, 2026 – The U.S. Food and Drug Administration (FDA) has granted traditional (full) approval to Kite’s CAR T-cell therapy, […]
• Eylea HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
  03.04.2026
  TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved […]
• FDA Approves Foundayo (orforglipron), the Only GLP-1 Pill for Weight Loss That Can be Taken Any Time of Day Without Food or Water Restrictions
  01.04.2026
  INDIANAPOLIS, April 1, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for […]
• Vertex Announces US FDA Approval for Label Extensions of Alyftrek and Trikafta, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
  01.04.2026
  BOSTON–(BUSINESS WIRE)–Apr. 1, 2026– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) […]
• FDA Approves Ponlimsi (denosumab-adet), a Biosimilar to Prolia
  01.04.2026
  TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United […]